This randomized, double-blind, placebo-controlled, cross-over study was conducted to evaluate the safety and efficacy of two-weeks of nightly sublingual cannabinoid extract (ZTL-101) in treating chronic insomnia (symptoms ≥three months).
The post Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy appeared first on Society of Cannabis Clinicians.